Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
sjZMdXSjs09Rw7BN